Search results for "Nucleoside analogue"

showing 8 items of 8 documents

“Open Sesame?”: biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity…

2020

Simple Summary Despite the enormous advance in biomarker discovery, many potential biomarkers of drug activity are unable to satisfy the clinical need due to inadequate sensitivity and specificity. The nucleoside transporter hENT-1 has been studied as a potential biomarker to predict the effect of the widely used anticancer drug gemcitabine in pancreatic cancer. However, several studies showed controversial results regarding the predictive value of hENT-1, prompting new analyses with larger cohorts of patients and standardized methodologies. Improved insights on molecular mechanisms underlying hENT-1 expression and activity should also help in the identification of subsets of patients who a…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyFOLFIRINOXpancreatic cancerSettore BIO/05 - Zoologiaclinical outcomeDUCTAL ADENOCARCINOMAEquilibrative nucleoside transporter 1lcsh:RC254-282Articlehuman equilibrative nucleoside transporter 103 medical and health sciences0302 clinical medicinePancreatic cancerInternal medicinemedicine1112 Oncology and CarcinogenesisScience & Technologydrug resistanceROLESNucleoside analoguebiology1 HENT1business.industryCombination chemotherapyCHEMOTHERAPYlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaGemcitabineRegimenLEVELS PREDICT RESPONSE030104 developmental biologyOncology030220 oncology & carcinogenesisCELLSMETASTASISbiology.proteinSURVIVALBiomarker (medicine)ADJUVANT GEMCITABINEbusinessLife Sciences & BiomedicineRESISTANCEmedicine.drug
researchProduct

A phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in metastatic colorectal cancer.

2017

TPS3626 Background: Trifluridine/tipiracil, also known as TAS‐102, is a combination of an antineoplastic thymidine‐based nucleoside analogue (trifluridine) and a thymidine phosphorylase inhibitor (tipiracil hydrochloride). The antitumor activity of combined trifluridine/tipiracil and oxaliplatin has been studied in gastrointestinal tumor xenografts, including a 5‐FU resistant subline, using a nude mouse model. This study demonstrated increased antitumor activity for the combination compared to trifluridine/tipiracil or oxaliplatin alone (p < 0.001) (Nukatsuka et al., Anticancer Res 2015). These data support the rationale for clinical use of the combination. We describe a phase 1, intern…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyNucleoside analogueColorectal cancerbusiness.industryTrifluridinemedicine.diseaseOxaliplatin03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineOncologychemistry030220 oncology & carcinogenesisInternal medicinemedicineDose escalationThymidine phosphorylasebusinessThymidinemedicine.drugTipiracilJournal of Clinical Oncology
researchProduct

Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis

1999

Nucleoside analogue-induced lactic acidosis is an often fatal condition in patients with HIV. There is only one report of successful treatment with riboflavin. We describe a 30-year-old female with AIDS and nucleoside analogue-induced lactic acidosis that exacerbated shortly after introducing total parenteral nutrition and reversed within hours after the addition of thiamine. Successful treatment of nucleoside analogue-induced lactic acidosis with a high dose of thiamine supports the hypothesis that vitamin deficiency is an important cofactor in the development of this rare and unpredictable condition in patients with HIV. We suggest that high dose B-vitamins should be given to any patient …

AdultAnti-HIV AgentsPharmacologymedicineHumansThiamineAcidosisAcquired Immunodeficiency SyndromeNucleoside analoguebusiness.industryfood and beveragesMetabolic acidosismedicine.diseaseDidanosineStavudineB vitaminsAnesthesiology and Pain MedicineBiochemistryLactic acidosisAcidosis LacticFemaleParenteral Nutrition TotalThiaminemedicine.symptombusinessSevere lactic acidosisNucleosidemedicine.drugEuropean Journal of Anaesthesiology
researchProduct

The Downside of an Effective cART: The Immune Restoration Disease

2013

The prognosis of patients infected with human immunodeficiency virus (HIV) type 1 has dramatically improved since the advent of the highly active antiretroviral therapy (HAART), which have enabled sustained suppression of HIV replication and recovery of CD4+ T cells count [1-3]. However, many patients in resource-poor settings still start HAART at a late stage of HIV infection when they already have advanced immunodeficien‐ cy [4,5]. Immune reconstitution in HIV infected patients is characterized by replenishment of immune cells depleted directly or indirectly by HIV infection, by regeneration of primary and secondary lymphoid organs, by restoration of pathogen-specific T, B and NK cells an…

CartSettore MED/17 - Malattie InfettiveNucleoside analoguebusiness.industryRegeneration (biology)HIV IRISDiseasemedicine.diseaseZidovudineImmune systemImmune reconstitution inflammatory syndromeDelayed hypersensitivityImmunologyMedicinebusinessmedicine.drug
researchProduct

From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-me…

2014

We synthesized a series of serum-stable covalently linked drugs derived from 3'-C-methyladenosine (3'-Me-Ado) and valproic acid (VPA), which are ribonucleotide reductase (RR) and histone deacetylase (HDAC) inhibitors, respectively. While the combination of free VPA and 3'-Me-Ado resulted in a clear synergistic apoptotic effect, the conjugates had lost their HDAC inhibitory effect as well as the corresponding apoptotic activity. Two of the analogs, 2',5'-bis-O-valproyl-3'-C-methyladenosine (A160) and 5'-O-valproyl-3'-C-methyladenosine (A167), showed promising cytotoxic activities against human hematological and solid cancer cell lines. A167 was less potent than A160 but had interesting featu…

Deoxyribonucleoside triphosphateAdenosineCell SurvivalClinical BiochemistryAllosteric regulationPharmaceutical ScienceAntineoplastic AgentsPharmacologyBiochemistryHistone deacetylase (HDAC) inhibitorHistone DeacetylasesAdenosine TriphosphateAllosteric RegulationCell Line TumorDrug DiscoveryRibonucleotide ReductasesmedicineValproic acidHumansRibonucleotide reductase (RR) inhibitorEnzyme InhibitorsMolecular Biology3′-C-methyladenosineNucleoside analogueKinaseChemistryOrganic ChemistryApoptosiEstersSettore CHIM/08 - Chimica FarmaceuticaHematological and solid tumorHistone Deacetylase InhibitorsKineticsRibonucleotide reductaseBiochemistrySettore BIO/14 - FarmacologiaMolecular MedicineHistone deacetylaseNucleosideIntracellularmedicine.drug
researchProduct

Changes in protein domains outside the catalytic site of the bacteriophage Qβ replicase reduce the mutagenic effect of 5-azacytidine.

2014

ABSTRACT The high genetic heterogeneity and great adaptability of RNA viruses are ultimately caused by the low replication fidelity of their polymerases. However, single amino acid substitutions that modify replication fidelity can evolve in response to mutagenic treatments with nucleoside analogues. Here, we investigated how two independent mutants of the bacteriophage Qβ replicase (Thr210Ala and Tyr410His) reduce sensitivity to the nucleoside analogue 5-azacytidine (AZC). Despite being located outside the catalytic site, both mutants reduced the mutation frequency in the presence of the drug. However, they did not modify the type of AZC-induced substitutions, which was mediated mainly by …

Mutation rateImmunologyMutantRNA-dependent RNA polymeraseBiologyVirus ReplicationMicrobiologyViral ProteinsVirologyCatalytic DomainmedicineGeneticsAllolevivirusNucleoside analogueQ beta Replicasebiology.organism_classification3. Good healthProtein Structure TertiaryViral replicationBiochemistryAmino Acid SubstitutionGenetic Diversity and EvolutionInsect ScienceAzacitidineQ beta ReplicaseBacteriophage QβNucleosidemedicine.drugMutagensJournal of virology
researchProduct

Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study

2011

Abstract Background and purpose Fludarabine is an adenine nucleoside analogue that has significant activity in hematological malignancies and has shown promising activity in combination with radiation in preclinical solid tumor models. We designed a phase I trial exploring concurrent fludarabine and radiotherapy in patients with advanced non-small cell lung cancer (NSCLC) to determine the maximum tolerated dose (MTD) of fludarabine given with concurrent irradiation. Materials and methods Thirteen patients with stage IIIB NSCLC received thoracic irradiation of 60 Gy. Fludarabine was administered during the 5th and 6th week of radiotherapy. Doses started at 10 mg/m2 per day and increased by s…

Oncologymedicine.medical_specialtyCancer ResearchRadiation-Sensitizing AgentsLung Neoplasmsmedicine.medical_treatmentAntineoplastic AgentsNSCLCMedicine & Public Health; Hematology; Oncology; Internal Medicine; Cancer Research03 medical and health sciencesFludarabine0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungCarcinomaMedicineCombined Modality TherapyHumansConcurrent fludarabine and radiotherapy030304 developmental biologyNeoplasm Staging0303 health sciencesOriginal PaperHematologyNucleoside analoguebusiness.industryRadiotherapy DosageGeneral MedicineAdenine nucleosideRadiochemotherapy in stage III NSCLC locally advanced inoperable NSCLCNucleoside analoguemedicine.diseaseCombined Modality Therapy3. Good healthFludarabinerespiratory tract diseasesClinical trialRadiation therapyOncology030220 oncology & carcinogenesisRadiotherapy phase I studybusinessFludarabine; NSCLC; Nucleoside analogue; Concurrent fludarabine and radiotherapy; Radiotherapy phase I study; Radiochemotherapy in stage III NSCLC locally advanced inoperable NSCLCVidarabinemedicine.drug
researchProduct

Synthesis and preliminary biological evaluation of a new pyridocarbazole derivative covalently linked to a thymidine nucleoside as a potential target…

2003

The therapy of human cancer is one of the more pursued goals by medicinal chemistry research. Most of the compounds clinically used as a treatment owe their efficacy to their cytotoxic interaction (direct or indirect) with nuclear DNA. This interaction results in the inhibition of DNA synthesis and the degradation of nucleic strands. Ellipticine is a naturally occurring 6H-pyrido[4,3-b]carbazole alkaloid endowed with antitumor activity, and several ellipticine derivatives have been used in clinical trials. We previously reported some 1,4-dimethyl-9H-carbazole derivatives structurally related to ellipticine. The purpose of our research was to transform the pyridocarbazole in a prodrug so tha…

PyridonesCarbazolesDrug Evaluation PreclinicalAntineoplastic Agentschemistry.chemical_compoundDrug Delivery SystemsCell Line TumorDrug DiscoveryHumansCytotoxicitynucleoside analogueDNA synthesisBiological activityGeneral ChemistryGeneral MedicineProdrugorganic synthesisPyrimidine NucleosidesBiochemistrychemistryNucleic acidantitumour activityThymidineNucleosideDNAThymidineChemicalpharmaceutical bulletin
researchProduct